Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biotechnology Index NYSE ETF (NY: FBT )

154.11 USD UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Jan 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biotechnology Index NYSE ETF

Biotech ETFs That Outperformed Last Week
Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer. 
Tags ETFs Pharma/Biotech Market News
From TalkMarkets
Look Under The Hood: FBT Has 33% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Biotech ETFs To Benefit From Latest Booster Update
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Tags ETFs Pharma/Biotech Stocks / Equities
From TalkMarkets
FBT Crosses Below Key Moving Average Level
In trading on Monday, shares of the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT) crossed below their 200 day moving average of $167.35, changing hands as low as $166.22 per share. First... 
Tags ETFs
From ETF Channel
How The Pieces Add Up: FBT Targets $208
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
We Did The Math FBT Can Go To $206
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Q2 Growth 'Nothing Short Of Virtuous': Economist
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe ... 
Tags Benzinga Health Care General
From Benzinga
Look Under The Hood: FBT Has 18% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Top-Performing Biotech ETFs of Last Week
Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week. 
From TalkMarkets
How The Parts Add Up: FBT Targets $202
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
Will Biotech ETFs Benefit from Biogen’s New Alzheimer’s Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen’s Alzheimer’s disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators... 
From ETF Trends
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
From TalkMarkets
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen ... 
From Benzinga
Medical Miracles Inside Biotech ETFs
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and... 
From TalkMarkets
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
From TalkMarkets
Analysts Forecast 22% Upside For The Holdings of FBT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
How The Parts Add Up: FBT Targets $211
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
FBT's Underlying Holdings Could Mean 16% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
Analysts Expect FBT To Hit $207
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
How The Pieces Add Up: FBT Targets $202
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
Analysts Anticipate 20% Gains Ahead For The Holdings of FBT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
From ETF Channel
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when ... 
From Benzinga
ETF Sectors to Bet on Positive Vaccine News
The aggravating coronavirus outbreak in the United States and globally is definitely increasing the desperation for a vaccine 
From TalkMarkets
Large Cap Biopharma Performance and Metrics Q3 2020; ETFs Are Winners
Surging coronavirus infections has even nicked the healthcare sector down 3% for the week. 
From TalkMarkets
Thursday's ETF Movers: TAN, FBT
In trading on Thursday, the Invesco Solar ETF is outperforming other ETFs, up about 10.9% on the day. Components of that ETF showing particular strength include shares of Jinkosolar Holding, up about... 
From ETF Channel
Wednesday's ETF Movers: FBT, KRE
In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 6.4% on the day. Components of that ETF showing particular strength include shares... 
From ETF Channel
Can’t Get Enough Biotech Exposure in Your Portfolio?
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds,... 
From ETF Trends
Not Enough Biotech in Your Portfolio?
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds,... 
From ETFdb
ETF Wrap: the Groundhog Day of fiscal stimulus talks and the bet on volatility
ETF Wrap is a briefing of what investors need to know in the exchange-traded fund sector, including exclusive commentary and interviews on the industry from MarketWatch 
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.